Related Experiment Video
Updated: Jul 14, 2026
07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis
Stephen M Colgan1, Som Mukherjee, Pierre Major
1Department of Medicine, Juravinski Cancer Center, Hamilton, Ontario.
Clinical Colorectal Cancer
|May 29, 2007
Summary
This review explores tumor angiogenesis and antiangiogenic therapies for colorectal cancer (CRC). Understanding tumor growth pathways and inhibitors offers potential for more effective CRC treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Colorectal cancer (CRC) remains a significant cause of cancer mortality, with poor survival rates for metastatic disease despite chemotherapy advances.
- Tumor growth and metastasis are critically dependent on angiogenesis, the formation of new blood vessels.
- Targeted antiangiogenic therapies show promise but require a deeper understanding of underlying mechanisms.
Purpose of the Study:
- To review the fundamental science of tumor angiogenesis.
- To discuss recent clinical trial outcomes for angiogenic inhibitors in cancer treatment.
- To explore the potential of combination therapies involving angiogenesis inhibitors for advanced colorectal cancer.
Main Methods:
- Literature review of basic science principles of tumor angiogenesis.
- Analysis of published clinical trial data on antiangiogenic agents.
- Synthesis of biological pathways regulating tumor growth and angiogenesis.
Main Results:
- Angiogenesis is a key process in tumor progression and a viable therapeutic target.
- Clinical trials demonstrate the efficacy of targeting growth factors involved in angiogenesis and tumor proliferation.
- Combination treatments may enhance therapeutic benefits of angiogenesis inhibitors.
Conclusions:
- A comprehensive understanding of tumor angiogenesis is crucial for developing novel colorectal cancer therapies.
- Antiangiogenic therapies represent a promising strategy for improving outcomes in advanced colorectal cancer.
- Further research into combination strategies holds potential for maximizing treatment efficacy.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...